US Edition
News from The Regulatory Review
Top The Regulatory Review News
Stock Markets · United StatesReplimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.See the Story
FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks - Replimune Group (NASDAQ:REPL)
60% Center coverage: 5 sources
Health Care · United StatesIn an effort to protect patients from unexpectedly high medical bills for emergency services and certain non-emergency services from out-of-network providers, Congress enacted the No Surprises Act on December 27, 2020. Because patients often cannot choose their provider in emergencies, they may unknowingly receive care from an out-of-network provider and face large bills when insurers refuse to cover the full amount. The Act seeks to limit these…Read Article
